Postinflammatory hyperpigmentation - I-Postinflammatory Hyperpigmentation
I-Postinflammatory Hyperpigmentation (Postinflammatory hyperpigmentation) yimeko yesikhumba ebonakala ngokunyuka kwebala eluswini emva kokudumba kolusu. i-postinflammatory hyperpigmentation (postinflammatory hyperpigmentation) inokubangelwa kukukhanya kwelanga ixesha elide, ukuvuvukala, okanye ezinye iingozi zesikhumba, kubandakanywa nezo zihambelana ne-acne. Abantu abanolusu olumnyama badla ngokuthanda ukuba ne-hyperpigmentation kunye nokuba sesichengeni selanga ngokugqithisileyo.
☆ Kwiziphumo zika-2022 ze-Stiftung Warentest ezivela eJamani, ukwaneliseka kwabathengi ngeModelDerm bekungaphantsi kancinci kunokubonisana nge-telemedicine ehlawulweyo.
References
Postinflammatory hyperpigmentation (PIH) yingxaki yesikhumba rhoqo eyenzekayo emva kokudumba okanye ukwenzakala kolusu. Ithanda ukuhlala ixesha elide kwaye imbi kakhulu kubantu abanesikhumba esimnyama (Fitzpatrick skin types III–VI) . Nangona isoloko isibangcono ngokwayo, oku kunokuthatha ixesha, ngoko ke unyango lusoloko lufuneka ixesha elide. Ukudibanisa unyango olwahlukileyo lusebenza ngcono.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation lulandelelwano oluqhelekileyo lokudumba kwesikhumba. Idla ngokuchaphazela abantu abanolusu oluntsundu kakhulu kwaye rhoqo. Uphononongo lubonisa ukuba imiba efana ne- postinflammatory hyperpigmentation iphakathi kwezizathu eziphambili zokuba kutheni abantu abanolusu olumnyama bafune ukhathalelo lwe-dermatological. Unyango lwakwangoko lubalulekile ekusombululeni postinflammatory hyperpigmentation kwaye ngokwesiqhelo iqala ngokulawula imeko yokuqala yokudumba. Umgca wokuqala wonyango ubandakanya ukusebenzisa ii-agent ezikhanyisa ulusu kunye ne-sunscreen ukukhusela. Ezi arhente, njenge hydroquinone, azelaic acid, kojic acid, arbutin, licorice extracts , zinokunciphisa ngokufanelekileyo umbala ogqithisileyo. Ukongeza, retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, soy zikwasetyenziswa njengeearhente zokususa umbala, kunye nonyango olutsha oluvelayo. Ngelixa unyango olusentloko luqhele ukusebenza kumphezulu womgangatho ophezulu wepigmentation, iinkqubo (laser, chemical peel) zingafuneka kwiimeko ezinenkani. Kubalulekile ukusebenzisa isilumkiso ngolu nyango ukunqanda ukucaphuka kunye nokuba mandundu kwe postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
